Sulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy
- 1 January 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 23 (1), 123-130
- https://doi.org/10.1681/asn.2011040378
Abstract
Sulodexide, a mixture of naturally occurring glycosaminoglycan polysaccharide components, has been reported to reduce albuminuria in patients with diabetes, but it is unknown whether it is renoprotective. This study reports the results from the randomized, double-blind, placebo-controlled, sulodexide macroalbuminuria (Sun-MACRO) trial, which evaluated the renoprotective effects of sulodexide in patients with type 2 diabetes, renal impairment, and significant proteinuria (>900 mg/d) already receiving maximal therapy with angiotensin II receptor blockers. The primary end point was a composite of a doubling of baseline serum creatinine, development of ESRD, or serum creatinine ≥6.0 mg/dl. We planned to enroll 2240 patients over approximately 24 months but terminated the study after enrolling 1248 patients. After 1029 person-years of follow-up, we did not detect any significant differences between sulodexide and placebo; the primary composite end point occurred in 26 and 30 patients in the sulodexide and placebo groups, respectively. Side effect profiles were similar for both groups. In conclusion, these data do not suggest a renoprotective benefit of sulodexide in patients with type 2 diabetes, renal impairment, and macroalbuminuria.Keywords
This publication has 38 references indexed in Scilit:
- Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathyNephrology Dialysis Transplantation, 2010
- Effects of sulodexide in patients with type 2 diabetes and persistent albuminuriaNephrology Dialysis Transplantation, 2008
- Sulodexide: A Renewed Interest in This GlycosaminoglycanCardiovascular Drug Reviews, 2006
- Antiproteinuric effect of oral paricalcitol in chronic kidney diseaseKidney International, 2005
- Standards of Medical Care for Patients With Diabetes MellitusDiabetes Care, 2003
- Nephropathy in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 1999
- A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patientsCurrent Medical Research and Opinion, 1997
- Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathyKidney International, 1994
- Human Pharmacokinetics of Glycosaminoglycans Using Deuterium-Labeled and Unlabeled Substances: Evidence for Oral AbsorptionSeminars in Thrombosis and Hemostasis, 1994
- Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic ratsKidney International, 1992